# US 2025/0084123 A1 · Multiproduct resin reuse (mrr) for the development and clinical manufacture of therapeutic proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084123 A1
- Document ID: US20250084123A1
- Status: Published application
- Kind: A1
- Application number: 18/798,969
- Filed: 2024-08-09
- Published: 2025-03-13
- Earliest claimed: 2023-08-14
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme LLC
- Inventors: Collette M. Cutler; Hong Li; Ren Liu; Jeffrey T. McPhee; Douglas Dennis Richardson, II; Patricia A. Rose; Patricia Rowicki
- Web page: https://patentgrep.com/patent/US20250084123A1

## CPC

- C07K 1/22: Affinity chromatography or related techniques based upon selective absorption processes
- C07K 1/18: Ion-exchange chromatography
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/065: {Purification, fragmentation}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides a method for multiproduct resin reuse (MRR) utilizing ionic exchange chromatography columns. The methods of the invention outline the cleaning steps necessary for reuse as well as the analytical processes used in determining product carryover from production of one product to the next. The invention outlines a successful MRR strategy that can be utilized not just in lab-scale studies, but in a GMP manufacturing setting.

## Claims

### Claim 1

A method to prepare a chromatography material used in the purification of a first polypeptide for reuse in the purification of a second polypeptide, the method comprising the steps of:
a) obtaining the chromatography material used in the purification of the first polypeptide, optionally wherein the first polypeptide has been eluted from the chromatography material;
b) passing one or more material volumes of regeneration buffer through the chromatography material, wherein the regeneration buffer comprises from about 0.05 M to about 2.0 M NaOH and a pH from about pH 12.0 to about pH 14.0;
c) incubating the chromatography material from about 0° C. to about 32° C. for at least from about 10 minutes to at least about 180 minutes in the presence of at least one of the one or more material volumes of regeneration buffer;
d) adding one or more material volumes of elution buffer to the chromatography material, wherein the elution buffer is formulated for use with the chromatography material and the first polypeptide;
e) optionally collecting the one or more material volumes of elution buffer from the chromatography material eluate, and optionally testing the one or more material volumes for the presence of the first polypeptide; and
f) equilibrating the chromatography material for reuse with the second polypeptide.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first and second polypeptides are the same or are different.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the first and second polypeptides are selected from the group consisting of: an enzyme; a hormone; a fusion protein; an Fc-containing protein; an immunoconjugate; a cytokine; and an antibody or antigen binding fragment thereof;
optionally wherein the antibody is selected from the group consisting of: a monoclonal antibody; a chimeric antibody; a humanized antibody; a human antibody; and a multispecific antibody:
optionally wherein the multispecific antibody is a bispecific antibody or a trispecific antibody; and
optionally wherein the antigen binding fragment thereof is selected from the group consisting of: a Fab fragment; a Fab′ fragment; a F(ab′)2 fragment; an scFv; a di-scFv; a bi-scFv; a tandem (di, tri) scFv; an Fv; a sdAb; a tri-functional antibody; a BiTE; a diabody; and a triabody.

### Claim at position 5

5-7. (canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein the first polypeptide has been eluted or has not been eluted from the chromatography material in step (a).

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the chromatography material comprises first and second chromatography materials; optionally wherein the first and second chromatography materials are operated discontinuously or continuously in series.

### Claim at position 9

11-12. (canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein one, two, three, four, five, or more than five material volumes of regeneration buffer is passed through the chromatography material.

### Claim at position 11

14-18. (canceled)

### Claim 19 (depends on 1)

The method of claim 1, wherein the regeneration buffer comprises about 0.05, 0.1, 0.5, 1.0, 1.5, or 2.0 M NaOH and a pH at about pH 13.0.

### Claim at position 13

20-24. (canceled)

### Claim 25 (depends on 1)

The method of claim 1, wherein the chromatography material is incubated at from about 20° C. to about 22° C. for at least about 10, 20, 40, 60, 120, or 180 minutes in the presence of at least one of the one or more material volumes of regeneration buffer.

### Claim at position 15

26-30. (canceled)

### Claim 31 (depends on 1)

The method of claim 1, wherein the chromatography material is selected from the group consisting of: an affinity chromatography material; an ion exchange chromatography material; a monolith chromatography material; a hydrophobic interaction chromatography material; and a mixed mode chromatography material;
optionally wherein the affinity chromatography material is a protein A affinity chromatography material;
optionally wherein the protein A affinity chromatography material is selected from the group consisting of: MabSelect; MabSelect SuRe; and MabSelect SuRe LX;
optionally wherein the ion exchange chromatography material is an anion exchange chromatography (AEX) material;
optionally wherein the AEX material is POROS 50HQ;
optionally wherein the ion exchange chromatography material is a cation exchange chromatography (CEX) material; and
optionally wherein the CEX material is Poros 50HS.

### Claim at position 17

32-37. (canceled)

### Claim 38 (depends on 1)

The method of claim 1, wherein the elution buffer comprises acetic acid and/or from about 0.01 M to about 0.5 M sodium acetate at a pH of from about pH 2.5 to about pH 5.0.

### Claim 39 (depends on 1)

The method of claim 1, wherein optionally testing the one or more material volumes of elution buffer for the presence of the first polypeptide comprises one or more analytical assay methods selected from the group consisting of: non-reduced sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS PAGE); ultra-performance liquid chromatography-size exclusion chromatography (UPLC-SEC); intact mass liquid chromatography-mass spectrometry (IM LC-MS); reduced peptide mapping (RPM); multiple reaction monitoring-liquid chromatography (LC-MRM); micro BCA; residual binding enzyme-linked immunosorbent assay (ELISA); and total organic carbon (TOC).

### Claim 40 (depends on 39)

The method of claim 39, wherein the first polypeptide is present in the one or more material volumes of elution buffer below a level of quantitation (LOQ) for the one or more analytical assay methods selected.

### Claim 41 (depends on 39)

The method of claim 39, wherein the first polypeptide is present in the one or more material volumes of elution buffer as one or more protein fragments, and wherein a total amount of polypeptide fragments are below an acceptable limit for a reference purity; optionally wherein the reference impurity is gelatin; and optionally wherein the acceptable limit is 650 μg/dose.

### Claim at position 22

42-43. (canceled)

### Claim 44 (depends on 1)

The method of claim 1, wherein the chromatography material is linked continuously or discontinuously to one or more preceding or subsequent chromatography materials.

### Claim 45 (depends on 1)

The method of claim 1, wherein the reused chromatography material is used to manufacture the second polypeptide at large scale, optionally wherein the large scale is a GMP scale.

### Claim 46

A method to prepare chromatography material used in the purification of a first polypeptide for reuse in the purification of a second polypeptide, the method comprising the steps of:
a) obtaining the chromatography material used in the purification of the first polypeptide, optionally wherein the first polypeptide has been eluted from the chromatography material;
b) passing one or more material volumes of regeneration buffer through the chromatography material, wherein the regeneration buffer comprises about 1.0 M NaOH at a pH of about pH 13.0;
c) incubating the chromatography material at from about 20° C. to about 22° C. for about 20 minutes in the presence of at least one of the one or more material volumes of regeneration buffer;
d) adding one or more material volumes of elution buffer to the chromatography material, wherein the elution buffer comprises from about 0.01 M to about 0.5 M sodium acetate at a pH of from about pH 2.5 to about pH 5.0;
e) optionally collecting the one or more material volumes of elution buffer from the chromatography material eluate, and optionally testing the one or more material volumes for the presence of the first polypeptide; and
f) equilibrating the chromatography material for reuse with the second polypeptide.

### Claim 47 (depends on 46)

The method of claim 46, wherein the first and second polypeptides have acceptable daily exposure or permitted daily exposure limits more than 10 μg/day; optionally wherein the first and second polypeptides have No-Observed-Effect-Level for systemic toxicity of ≥300 mg/kg/week.

### Claim 48

(canceled)

### Claim 49 (depends on 1)

A polypeptide produced or obtainable by the method of claim 1.

### Claim 50

(canceled)

### Claim 51 (depends on 49)

The polypeptide of claim 49, wherein the polypeptide is selected from the group consisting of: an enzyme; a hormone; a fusion protein, an Fc-containing protein; an immunoconjugate; a cytokine; and an antibody or antigen binding fragment thereof;
optionally wherein the antibody is selected from the group consisting of: a monoclonal antibody; a chimeric antibody; a humanized antibody; a human antibody; and a multispecific antibody;
optionally wherein the multispecific antibody is a bispecific antibody or a trispecific antibody; and
optionally wherein the antigen binding fragment thereof is selected from the group consisting of: a Fab fragment; a Fab′ fragment; a F(ab′)2 fragment; an scFv; a di-scFv; a bi-scFv; a tandem (di, tri) scFv; an Fv; an sdAb; a tri-functional antibody; a BiTE; a diabody; and a triabody.

### Claim at position 31

52-55. (canceled)

### Claim 56 (depends on 49)

A composition comprising a therapeutically effective amount of the polypeptide of claim 49, and a pharmaceutically acceptable carrier.
